Drug Trial Radar · NCT06855771
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Sep 9, 2025
Primary completion
Dec 29, 2028
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
BMS-986504Drug
Specified dose on specified days
Izalontamab BrengitecanDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 3 years after the last participant's last dose of study treatment
- Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteriaTime frame: Up to 28 days after the last dose of study treatment
- Number of participants with adverse events (AE)Time frame: Up to 28 days after the last dose of study treatment
- Number of participants with Serious AEs (SAEs)Time frame: Up to 28 days after the last dose of study treatment
- Number of participants with treatment related AEsTime frame: Up to 28 days after the last dose of study treatment
- Number of participants with treatment related SAEsTime frame: Up to 28 days after the last dose of study treatment
- Number of participants with AEs leading to study treatment discontinuationTime frame: Up to 28 days after the last dose of study treatment
- Number of participants with AEs leading to deathTime frame: Up to 28 days after the last dose of study treatment
- Number of participants with laboratory abnormalitiesTime frame: Up to 28 days after the last dose of study treatment
Locations
67 sites in 12 countries. Site status is shown where the registry gives one.
Local Institution - 0088
Anchorage, Alaska · Completed
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
Providence Portland Medical Center
Portland, Oregon · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Fred Hutchison Cancer Center
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
GenesisCare - Campbelltown
Campbelltown, New South Wales, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Local Institution - 0097
Adelaide, South Australia, Australia · Completed
Beijing Chest Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
LinYi Cancer Hospital
Linyi, Shandong, China · Recruiting
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province
Linhai, Zhejiang, China · Recruiting
Hopitaux Universitaires Paris Centre-Hopital Cochin
Paris, France · Recruiting
Institut Curie
Paris, France · Recruiting
Hôpital Tenon
Paris, France · Recruiting
Groupe hospitalier Paris saint Joseph
Paris, Île-de-France Region, France · Recruiting
Chu Grenoble Alpes
La Tronche, Isère, France · Recruiting
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
Saint-Herblain, Loire-Atlantique, France · Recruiting
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France · Recruiting
Hospices Civils de Lyon - Hopital Louis Pradel
Bron, Rhône, France · Recruiting
Universitaetsklinikum Koeln
Cologne, Germany · Recruiting
Universitaetsklinikum Wuerzburg
Würzburg, Germany · Recruiting
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Bavaria, Germany · Recruiting
Universitätsklinikum Frankfurt Goethe-Universität
Frankfurt am Main, Hesse, Germany · Recruiting
Krankenhaus Martha-Maria Halle-Dölau
Halle, Saxony-Anhalt, Germany · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
AOU della Campania Luigi Vanvitelli
Naples, Campania, Italy · Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Naples, Campania, Italy · Recruiting
Fondazione IRCCS San Gerardo dei Tintori
Monza, Lombardy, Italy · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.